Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
Alembic Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

₹959.9

2024-05-17

Market Capitalization

₹188.7 B

2024-05-17

Revenue

₹55 B

FY, 2023

CreditSafe Score

?
Score changed on May 25, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

INRFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023
Revenue31.2B39.3B45.9B52.8B52.3B55.0B
Cost of goods sold10.4B11.7B13.0B15.0B17.0B19.7B
Gross profit20.9B27.6B33.1B39.0B36.0B36.8B
Gross profit margin, %66.8%70.4%72.1%73.8%68.9%66.9%
Operating expense total14.7B19.0B20.3B24.1B27.2B29.7B
Depreciation and amortization1.1B1.2B2.1B1.8B2.9B2.8B
EBITDA6.2B8.6B12.8B14.9B8.8B6.8B
EBITDA margin, %19.7%21.9%27.8%28.2%16.9%12.4%
EBIT5.1B7.4B10.1B13.0B6.0B4.1B
EBIT margin, %16.3%18.9%22.1%24.7%11.4%7.4%
Interest income6.2M25.8M17.3M15.8M17.3M3.3M
Interest expense34.0M184.1M271.6M160.2M177.3M501.7M
Pre tax profit5.4B7.5B10.0B13.7B6.2B3.5B
Income tax expense1.2B1.6B2.0B2.5B1.0B126.0M
Net Income4.2B5.9B8.0B11.1B5.2B3.4B

Footer menu